PRESCIENT THERAPEUTICS LIMITED 30 November 2015
Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukaemias.
This is of particular interest to PTX ahead of an upcoming clinical trial in Acute Myeloid Leukaemia (AML) in early 2016.
Professor Lancet was an investigator on PTX's earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.
The study showed that 17 out of 32 patients had stable disease after one cycle of treatment and 3 patients with AML had >50% bone marrow blast reduction.
These encouraging results demonstrated that further investigation of PTX-200 is warranted, either as a stand- alone treatment or as a combination therapy in patients with high Akt levels.
Professor Lancet said: 'I am delighted to join the Company's SAB, particularly as I am very familiar with PTX- 200 and its Akt inhibitor activity. I look forward to working closely with Chief Scientific Officer Professor Said Sebti when we open the Phase 1b AML trial here at Moffitt early next year.'
PTX Chairman Steve Engle said, 'Professor Lancet is an outstanding clinician and researcher. Having him as the Principal Investigator on our forthcoming Phase 1b trial in AML at Moffitt, is most reassuring to patients and the Company.'
'This appointment follows on from the recent appointment of Professor Farhad Ravandi from MD Anderson to the Company's SAB. Investors in our Company can be assured we have first-rate expertise in AML, with international experts from world renowned institutions. We look forward to updating investors as we achieve key milestones.'
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
ASX ANNOUNCEMENT
PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for Acute Myeloid Leukaemia.
PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.
Further Inquiries: Steven Engle | Paul Hopper | Rudi Michelson |
Chairman +1 858 922 7768 (US) | Executive Director +61 406 671 515 | Monsoon Communications +61 3 9620 3333 |
|
distributed by
|
